Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs
Pune, India -- (SBWIRE) -- 06/25/2018 -- Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations.
Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response.
This report covers all immunological disorders, but there is a particular focus on four key diseases, rheumatoid arthritis, psoriasis, inflammatory bowel disease and graft versus host disease/transplant rejection, as these conditions have the largest pipelines within the therapy area.
The market size for immunology therapeutics was valued at $65.1 billion in 2016 and it is expected to grow at a compound annual growth rate (CAGR) of 8.2% to $113 billion in 2023.
Get Sample Report at http://www.rnrmarketresearch.com/contacts/request-sample?rname=1512401
Reasons to buy
Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.
Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.
Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.
Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
browse Complete Report at http://www.rnrmarketresearch.com/global-immunology-drugs-market-to-2023-shifting-landscape-as-uptake-of-interleukin-receptor-inhibitors-offsets-losses-for-top-blockbuster-drugs-market-report.html
Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.
Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.